GLP-1 and GLP-1/GIP RAs for obstructive sleep apnoea – What is their role?

Prof Brendon Yee

writer

Prof Brendon Yee

Respiratory and Sleep Medicine Physician; Woolcock Institute of Medical Research; Staff Specialist and Medical Director of Respiratory Failure Services, Royal Prince Alfred Hospital; Consultant, Rural Outreach Services

Claim CPD for this activity

Educational Activities (EA)

0.5 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0.5 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

1 hours

These are activities that use your work data to ensure quality results.

EA
0.5 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0.5 minutes

These are activities that require reflection on feedback about your work.

MO
1 minutes

These are activities that use your work data to ensure quality results.

Prof Brendon Yee

How new evidence will change how we assess and manage OSA

With obesity demonstrating mortality rates comparable to cigarette smoking, and obstructive sleep apnoea (OSA) potentially affecting up to one billion people worldwide, the intersection of these conditions demands innovative therapeutic approaches.

Recent advances in incretin-based therapies, particularly the GLP-1/GIP receptor agonist tirzepatide (Mounjaro), are revolutionising treatment for patients with concurrent obesity and OSA, offering clinically significant improvements that may challenge traditional CPAP-centric management strategies.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

References

  1. Benjafield AV, et al. Lancet Respir Med. 2019;7(8):687–98.
  2. Nieto FJ, et al. 2000;283(14):1829–36.
  3. Hedner J, et al. Eur Respir J. 2011;38(2):434–42.
  4. Peppard PE, et al. 2000;284(23):3015–21.
  5. Malhotra A, et al. Sleep Med. 2024;121:11.
  6. Davies MJ, et al. Diabetes Care. 2016;39(11):1972–80.
  7. Wilding JPH, et al. N Engl J Med. 2021;384(11):989–1002.
  8. Malhotra A, et al. N Engl J Med. 2024;391(15):1464–75.
  9. Azarbarzin A, et al. Eur Heart J. 2019;40(14):1149–57.
  10. Bratton DJ, et al. 2015;314(21):2280–93.
  11. Jastreboff AM, et al. N Engl J Med. 2025;392:958–71.
  12. Aronne LJ, et al. 2024;331(1):38–48.
  13. Jastreboff AM, et al. N Engl J Med. 2023;389:514–26.
  14. Gabryelska A, et al. J Clin Med. 2022;11(1):139.
  15. Javaheri S, et al. Chest. 2019;156(3):321–30.
  16. Abushamat LA, et al. Curr Cardiol Rep. 2024;26(7):739–47.
  17. Rubino F, et al. Nat Rev Endocrinol. 2020;16(12):715–16.
  18. Zhang Y, et al. Diabetes Obes Metab. 2023;25(11):2915–27.
  19. Loomba R, et al. N Engl J Med. 2023;389(4):336–49.
  20. Packer M, et al. N Engl J Med. 2023;389(12):1085–95.
  21. Siniukovich A, et al. Diabetol Metab Syndr. 2025;17:247.
  22. Bliddal H, et al. N Engl J Med. 2024;391(15):1464–75.
  23. Leggio L, et al. N Engl J Med. 2023;389(15):1399–409.
  24. Douros A, et al. Lancet Diabetes Endocrinol. 2024;12(5):327–36.
  25. Samms RJ et al. Trends in Endocrinology & Metabolism, 31 (6), 2020, 410-421.

Further your CPD learning

Based on this educational activity, complete these learning modules to gain additional CPD.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof William Kemp

A/Prof William Kemp

Cardiovascular Risk and Fatty Liver Disease

Dr Ryan De Cruz

Dr Ryan De Cruz

Importance of Early & Effective Treatment of Mild to Moderate Acne

Prof Merlin Thomas

Prof Merlin Thomas

SGLT2s and Renal Protection

Dr Adam Nelson

Dr Adam Nelson

CV Medications – Practical Strategies to Improve Compliance

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof Brendon Yee

writer

Prof Brendon Yee

Respiratory and Sleep Medicine Physician; Woolcock Institute of Medical Research; Staff Specialist and Medical Director of Respiratory Failure Services, Royal Prince Alfred Hospital; Consultant, Rural Outreach Services

Test your knowledge

Recent articles

Latest GP poll

To what extent is government messaging contributing to public perception of "greedy doctors"?

Significantly

0%

Slightly contributing

0%

Not at all contributing

0%

I don't think there is a public perception of greedy doctors

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Upcoming Healthed Webcast

Cardiovascular Risk and Fatty Liver Disease

Tuesday 11th November, 7pm - 9pm AEDT

Speaker

A/Prof William Kemp

Gastroenterologist and Hepatologist; Alfred Hospital Melbourne, Monash University School of Translational Medicine

We invite you to our next free webcast, where I will discuss cardiovascular risk and fatty liver disease. Earn up to 4 hours CPD. RACGP & ACRRM accredited.